New data show 22.1% weight loss at one year with consecutive Allurion Balloons, approaching weight loss surgery outcomes

Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced three scientific presentations at the American Society for Metabolic and Bariatric Surgery Annual Meeting (ASMBS) taking place in San Diego, California, June 9-13, 2024.

Data from a study of 121 patients across 11 obesity centers treated with two consecutive, four-month Allurion Balloons showed patients achieved 22.1% weight loss on average at one year. In comparison, studies show that patients treated with 12-month endoscopic intragastric balloons achieve 15.4%1 and 16.2%2 total body weight loss*. “We believe these findings underscore the potential of the Allurion Balloon to deliver superior outcomes to other intragastric balloons, approaching those of weight loss surgery,3,4 for patients seeking effective and safe weight loss solutions,” said Dr. Shantanu Gaur, Founder and CEO of Allurion.

Evidence from multiple studies indicates that the Allurion Balloon—a procedureless, liquid-filled balloon—has a significantly lower intolerance rate compared to 12-month endoscopic balloons (1-3% vs 14.4%)5, with an overall serious adverse event rate that averages 10 times less than other liquid-filled balloons*.

Presentations also include data from a study analyzing 1,313 conversations from patients across 26 bariatric clinics in 12 countries and Coach Iris – Allurion’s AI-powered weight loss coach – assessing the safety, accuracy, and overall quality of a beta version released in 2023.

Conversations between patients and Coach Iris were reviewed against a unique framework developed in-house and recently presented at IFSO-EC. Named “FAST,” this framework is designed to evaluate and monitor the Fidelity, Accuracy, Safety, and Tone of Coach Iris. The text-based, human-like messaging received satisfaction scores of 84% on Fidelity, 79% on Accuracy, 89% on Safety, and 95% on Tone.

Presentations at ASMBS also include data on the impact of digital appetite tracking and eating behaviors in Allurion Balloon Program patients.

Details of the presentations are as follows:

Title: Consecutive 4-Month Swallowable Balloon Weight Loss Surpasses Results of a Single 12-Month Endoscopic Balloon and Approaches Weight Loss Surgery Results Presenter: Roberta Ienca, M.D., Weight Management Center, Nuova Villa Claudia Clinic

Title: A Novel Conversational Agent Fine-Tuned for Bariatric Treatment Provides Safe and Accurate Patient Care: A Multi Country Study Presenter: Martha Neary, M.Sc., Senior Manager Behavioral Medicine, Allurion

Title: Digital Tracking of Hunger and Fullness Enhances Awareness of Appetite, Food Choices and Portion Sizes in Patients with a Swallowable Gastric Balloon Presenter: Zoe Griffiths, Bsc,. RD, Senior Director Behavioral Medicine, Allurion

For more information about ASMBS 2024, please visit: https://asmbsmeeting.com/about/

* The Allurion Balloon was not compared in head-to-head studies with any other gastric balloons.

Sources: 1. Obes Surg. 2024;34(1):176-182. doi:10.1007/s11695-023-06953-0; 2. Obes Surg. 2021;31(12):5342-5347. doi:10.1007/s11695-021-05729-8; 3. Obes Surg. 2021;31:3833–3847. https://doi.org/10.1007/s11695-021-05394-x); 4. ANZ J Surg. 2021;91(11):2443-2446. doi:10.1111/ans.17233; 5. Obes Surg. 2021;31(12): 5342-5347.

About Allurion

Allurion is dedicated to ending obesity. The Allurion Program is a weight loss platform that features the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-less intragastric balloon for weight loss, and offers access to the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers, Allurion Insights for health care providers featuring the Coach Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor and manage weight loss therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional. The Allurion Gastric Balloon is an investigational device in the United States.

For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com

Allurion is a trademark of Allurion Technologies, Inc. in the United States and countries around the world.

Forward-Looking Statements

This press release may contain certain forward-looking statements within the meaning of the U.S. federal and state securities laws. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions and include statements regarding the ability of the Allurion Balloon to deliver superior outcomes for patients seeking safe and effective treatment options. Forward-looking statements are predictions, projections and other statements about future events that reflect the current beliefs and assumptions of Allurion’s management based on information currently available to them and, as a result, are subject to risks and uncertainties. Many factors could cause actual future results or developments to differ materially from the forward-looking statements in this communication, including but not limited to (i) the ability of Allurion to obtain and maintain regulatory approvals for and successfully commercialize the Allurion Program, including the Allurion Balloon and the VCS, (ii) the timing of, and results from, our clinical studies and trials, (iii) the evolution of the markets in which Allurion competes, (iv) the ability of Allurion to defend its intellectual property, (v) the impact of the COVID-19 pandemic, the Russia and Ukraine war, and the Israel-Hamas conflict on Allurion’s business, (vi) Allurion’s expectations regarding its market opportunities, including those for the VCS platform, and (vii) the risk of economic downturns and a changing regulatory landscape in the highly competitive industry in which Allurion operates. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Allurion’s Annual Report on Form 10-K filed on March 26, 2024 (as subsequently amended) and other documents filed by Allurion from time to time with the U.S. Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Allurion assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Allurion does not give any assurance that it will achieve its expectations.

Global Media: Cedric Damour PR Manager +33 7 84 21 02 20 cdamour@allurion.com Investors: Mike Cavanaugh, Investor Relations ICR Westwicke (617) 877-9641 mike.cavanaugh@westwicke.com

Allurion Technologies (NYSE:ALUR)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Allurion Technologies Charts.
Allurion Technologies (NYSE:ALUR)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Allurion Technologies Charts.